PMID- 28402945
OWN - NLM
STAT- MEDLINE
DCOM- 20180319
LR  - 20221207
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 23
DP  - 2017 Jun 6
TI  - A prospective, open-label, multicenter, observational study to evaluate the 
      efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for 
      autologous stem cell transplantation-ineligible patients with multiple myeloma.
PG  - 37605-37618
LID - 10.18632/oncotarget.16790 [doi]
AB  - Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as 
      first-line treatment for transplantation-ineligible multiple myeloma (MM). This 
      study investigated the efficacy of VMP for Korean patients with MM.Overall, 177 
      MM patients received 9 cycles of VMP in this prospective, multicenter, 
      observational study. The primary endpoint was 2-year progression-free survival 
      (PFS).Thirty-nine (22%) patients were aged >/= 75 years and 83 (47.4%) patients had 
      International Staging System stage III. A median of 5 cycles were delivered. 
      Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. 
      With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS 
      and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was 
      not reached. PFS was significantly different depending on performance status 
      (Eastern Cooperative Oncology Group < 2 vs. >/= 2; p = 0.0002), beta2-microglobulin 
      level (< 5.5 vs. >/= 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 
      35.1 vs. >/= 35.1 mg/m2; p < 0001). The common adverse events (AEs) were in line 
      with the well-known toxicity profiles associated with VMP.In conclusion, VMP is a 
      feasible and effective front-line treatment for transplant-ineligible older 
      patients with MM in Korea. Continuing therapy with prompt adjustment of treatment 
      according to AEs may be important to improve outcomes of elderly patients.
FAU - Kim, Min Kyoung
AU  - Kim MK
AD  - Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea.
FAU - Kim, Kihyun
AU  - Kim K
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Korea.
FAU - Min, Chang-Ki
AU  - Min CK
AD  - Division of Hematology, Department of Internal Medicine, Seoul St. Mary's 
      Hospital, The Catholic University of Korea, Seoul, Korea.
FAU - Kwak, Jae-Yong
AU  - Kwak JY
AD  - Department of Internal Medicine, Chonbuk National University Medical School, 
      Jeonju, Korea.
FAU - Bae, Sang-Byung
AU  - Bae SB
AD  - Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan, 
      Korea.
FAU - Yoon, Sung-Soo
AU  - Yoon SS
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Korea.
FAU - Lee, Je-Jung
AU  - Lee JJ
AD  - Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea.
FAU - Kim, Ki Hwan
AU  - Kim KH
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul, Korea.
FAU - Nam, Seung-Hyun
AU  - Nam SH
AD  - Department of Internal Medicine, VHS Medical Center, Seoul, Korea.
FAU - Mun, Yeung-Chul
AU  - Mun YC
AD  - Department of Internal Medicine, Ewha Womans University School of Medicine, 
      Seoul, Korea.
FAU - Kim, Hyo Jung
AU  - Kim HJ
AD  - Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym 
      University College of Medicine, Anyang, Korea.
FAU - Bae, Sung Hwa
AU  - Bae SH
AD  - Department of Internal Medicine, Catholic University of Daegu School of Medicine, 
      Daegu, Korea.
FAU - Shin, Ho-Jin
AU  - Shin HJ
AD  - Department of Internal Medicine, Division of Hematology/Oncology, School of 
      Medicine, Medical Research Institute, Pusan National University Hospital, Busan, 
      Korea.
FAU - Lee, Jung-Hee
AU  - Lee JH
AD  - Department of Hematology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Park, Joon Seong
AU  - Park JS
AD  - Department of Hematology/Oncology, Ajou University School of Medicine, Suwon, 
      Korea.
FAU - Jeong, Seong Hyun
AU  - Jeong SH
AD  - Department of Hematology/Oncology, Ajou University School of Medicine, Suwon, 
      Korea.
FAU - Lee, Mark Hong
AU  - Lee MH
AD  - Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
FAU - Kim, Yang-Soo
AU  - Kim YS
AD  - Department of Hematology/Oncology, Kosin University College of Medicine, Busan, 
      Korea.
FAU - Lee, Ho Sup
AU  - Lee HS
AD  - Department of Hematology/Oncology, Kosin University College of Medicine, Busan, 
      Korea.
FAU - Park, Keon Woo
AU  - Park KW
AD  - Department of Internal Medicine, Dankook University College of Medicine, Cheonan, 
      Korea.
FAU - Lee, Won-Sik
AU  - Lee WS
AD  - Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, 
      Korea.
FAU - Lee, Sang Min
AU  - Lee SM
AD  - Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, 
      Korea.
FAU - Lee, Jeong-Ok
AU  - Lee JO
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Gyeonggi-do, Korea.
FAU - Hyun, Myung Soo
AU  - Hyun MS
AD  - Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea.
FAU - Jo, Deog Yeon
AU  - Jo DY
AD  - Department of Hematology/Oncology, Chungnam National University Hospital, 
      Daejeon, Korea.
FAU - Lim, Sung-Nam
AU  - Lim SN
AD  - Department of Internal Medicine, Haeundae Paik Hospital, Inje University College 
      of Medicine, Busan, Korea.
FAU - Lee, Jae Hoon
AU  - Lee JH
AD  - Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, 
      Korea.
FAU - Cho, Do-Yeun
AU  - Cho DY
AD  - Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea.
FAU - Do, Young Rok
AU  - Do YR
AD  - Department of Internal Medicine, Keimyung University School of Medicine, Daegu, 
      Korea.
FAU - Kim, Jeong-A
AU  - Kim JA
AD  - Department of Hematology, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Park, Seong Kyu
AU  - Park SK
AD  - Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 
      Bucheon, Korea.
FAU - Kim, Jin Seok
AU  - Kim JS
AD  - Division of Hematology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Soo-Jeong
AU  - Kim SJ
AD  - Division of Hematology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Hawk
AU  - Kim H
AD  - Division of Hematology and Cellular Therapy, Ulsan University Hospital, 
      University of Ulsan College of Medicine, Ulsan, Korea.
FAU - Yi, Hyeon Gyu
AU  - Yi HG
AD  - Department of Internal Medicine, Inha University Hospital, Inha University School 
      of Medicine, Incheon, Korea.
FAU - Moon, Joon Ho
AU  - Moon JH
AD  - Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, 
      Korea.
FAU - Choi, Chul Won
AU  - Choi CW
AD  - Department of Internal Medicine, Korea University Guro Hospital, Korea University 
      College of Medicine, Seoul, Korea.
FAU - Kim, Sung-Hyun
AU  - Kim SH
AD  - Department of Internal Medicine, Dong-A Medical Center, Dong-A University College 
      of Medicine, Busan, Korea.
FAU - Joo, Young-Don
AU  - Joo YD
AD  - Department of Hemato-Oncology, Inje University Haeundae Paik Hospital, Busan, 
      Korea.
FAU - Kim, Hoon-Gu
AU  - Kim HG
AD  - Department of Internal Medicine, Gyeongsang Institute of Health Sciences, 
      Gyeongsang National University School of Medicine and Gyeongsang National 
      University Changwon Hospital, Changwon, Korea.
FAU - Kim, Byung Soo
AU  - Kim BS
AD  - Department of Hematology, Korea University Medical Center, Korea University 
      College of Medicine, Seoul, Korea.
FAU - Park, Moo-Rim
AU  - Park MR
AD  - Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, 
      Korea.
FAU - Song, Moo-Kon
AU  - Song MK
AD  - Department of Hemato-Oncology, Hanyang University Hanmaeum Changwon Hospital, 
      Changwon, Korea.
FAU - Kim, Su-Youn
AU  - Kim SY
AD  - Medical Affairs, Janssen Korea, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 69G8BD63PP (Bortezomib)
RN  - Q41OR9510P (Melphalan)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Asian People
MH  - Bortezomib/administration & dosage/adverse effects
MH  - Diarrhea/chemically induced
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Melphalan/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy/ethnology/pathology
MH  - Neoplasm Staging
MH  - Neutropenia/chemically induced
MH  - Prednisone/administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Republic of Korea
MH  - Treatment Outcome
PMC - PMC5514934
OTO - NOTNLM
OT  - aged
OT  - bortezomib
OT  - combination
OT  - drug therapy
OT  - multiple myeloma
COIS- CONFLICTS OF INTEREST The authors have no potential conflicts of interest.
EDAT- 2017/04/14 06:00
MHDA- 2018/03/20 06:00
PMCR- 2017/06/06
CRDT- 2017/04/14 06:00
PHST- 2016/09/20 00:00 [received]
PHST- 2017/01/10 00:00 [accepted]
PHST- 2017/04/14 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
PHST- 2017/04/14 06:00 [entrez]
PHST- 2017/06/06 00:00 [pmc-release]
AID - 16790 [pii]
AID - 10.18632/oncotarget.16790 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jun 6;8(23):37605-37618. doi: 10.18632/oncotarget.16790.